Background
Sodium gamma-hydroxybutyrate (GHB) — the active ingredient in Jazz Pharmaceuticals’ narcolepsy drug Xyrem — is a sedative with serious misuse potential, sometimes known on the street as a “date rape drug.” Because of these risks, the FDA conditioned its approval of Xyrem on Jazz implementing a Risk Evaluation and Mitigation Strategy (REMS) — a comprehensive drug safety program that controls how the medication is prescribed, dispensed, and tracked to prevent diversion and abuse.
Jazz held a patent — U.S. Patent No. 8,731,963 — that claimed the REMS system itself: the network of databases, pharmacies, and monitoring protocols that together implement the drug safety program. Jazz listed this patent in the FDA’s Orange Book, which is the official registry of patents claiming FDA-approved drugs or their methods of use. Orange Book listing is significant because it can delay generic competitors from obtaining FDA approval by triggering automatic 30-month stays under the Hatch-Waxman framework. Avadel CNS Pharmaceuticals was seeking approval for a competing once-nightly sodium oxybate product and challenged Jazz’s Orange Book listing, seeking to have the REMS patent delisted. The district court ordered delisting, and Jazz appealed.
The Court’s Holding
The Federal Circuit affirmed. The Hatch-Waxman Act permits Orange Book listing only for patents that claim “the drug” or a “method of using such drug” for which the NDA was submitted. Jazz’s ‘963 patent claimed the REMS system — a multi-component distribution and monitoring system — not the sodium oxybate drug itself or any method of treating patients with it. The court rejected Jazz’s argument that because patients could only access Xyrem by following the REMS procedures, the REMS patent effectively claimed a “method of using” the drug.
The Federal Circuit drew a critical distinction: a patent on a system for controlling how a drug is distributed and monitored is not the same as a patent on a therapeutic method of using that drug. The statute’s reference to “method of use” patents encompasses methods of treating diseases with the drug — clinical uses — not administrative or logistical systems that surround the drug’s distribution. The court affirmed the district court’s injunction directing Jazz to request FDA delisting of the ‘963 patent, a significant practical result that cleared the path for Avadel’s competing product.
Key Takeaways
- Only patents that literally claim the approved drug itself or a clinical method of using that drug for a patented indication qualify for FDA Orange Book listing — system, distribution, or monitoring patents do not.
- A REMS patent — even one that controls access to the drug in a way that is tightly integrated with its use — is not a “method of use” patent for Orange Book listing purposes.
- Improper Orange Book listing can be challenged in court, and courts can order delisting via injunction, removing a key litigation delay mechanism from the Orange Book-listed patent holder.
- The FTC has taken an increasingly active interest in improper Orange Book listings as an anticompetitive tool; this ruling aligns with that enforcement trend.
Why It Matters
This decision has significant implications for the pharmaceutical industry’s use of the Hatch-Waxman patent listing system. Brand-name drug companies have faced criticism — including from the Federal Trade Commission — for listing patents in the Orange Book that do not genuinely cover the drug or its therapeutic use, using these listings as a tactical tool to delay generic and biosimilar competitors. The ruling in Jazz v. Avadel draws a clear line: REMS system patents, however integral to drug distribution, are not listable.
For generic and biosimilar competitors, the case confirms that courts will scrutinize Orange Book listings and order delisting of patents that don’t meet statutory requirements. For brand-name companies, it is a reminder that aggressive listing strategies carry litigation risk: a successful delisting challenge removes both the listed patent and the 30-month stay protection it triggers, potentially accelerating generic market entry.